Ankylosing Spondylitis Drugs Market To Reach USD 8.82 Billion By 2027 | Reports And Data
February 11, 2020 16:00 ET
|
Reports and Data
New York, Feb. 11, 2020 (GLOBE NEWSWIRE) -- The global ankylosing spondylitis drugs market is forecast to reach USD 8.82 Billion by 2027, according to a new report by Reports and Data. Ankylosing...
Amarantus Announces Subsidiary MANF Therapeutics Enters Into Material Transfer Agreement with Dyadic International
February 06, 2020 08:11 ET
|
Amarantus Bioscience Holdings, Inc.
New York, NY, Feb. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a biotechnology holding company pursuing proprietary...
Avid Bioservices Appoints Timothy Compton as Chief Commercial Officer
January 08, 2020 08:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices Reports Financial Results for Second Quarter Fiscal 2020 and Recent Developments
December 09, 2019 16:05 ET
|
Avid Bioservices, Inc
-- Achieved Strong Second Quarter Revenue of $18.3 Million and Gross Margin of 18% -- -- Fiscal 2020 Projected Revenue of $64 to $67 Million Reaffirmed -- -- Launched Expanded Process Development...
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
December 04, 2019 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2020 After Market Close on December 9, 2019
December 02, 2019 08:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Cytovance® Biologics Introduces an Integrated Single-use Platform for Plasmid DNA (pDNA) Manufacture
October 21, 2019 12:00 ET
|
Cytovance Biologics
OKLAHOMA CITY, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Cytovance Biologics is a leading biopharmaceutical CDMO with a 15-year track record of supplying drug substance to clients, offering fast and...
Cytovance Biologics to Participate in RAFT Scientific Discussion on Commercialization of Fermentation Processes
October 18, 2019 17:24 ET
|
Cytovance Biologics
OKLAHOMA CITY, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the company will participate...
Avid Bioservices Names Richard Richieri as Chief Operations Officer
October 09, 2019 12:30 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices Announces Completion of Expansion of Process Development Capabilities and Laboratory Infrastructure
October 08, 2019 08:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...